• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS)

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


OSB Lead-NeuRx DPS

Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Progress Adequate
Application Number H100006 / PAS001
Date Current Protocol Accepted 09/28/2011
Study Name OSB Lead-NeuRx DPS
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group No Control
Analysis Type Descriptive
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Design Description This is a prospective, non-randomized, open-label, interventional study.
Study Population Description This study will enroll ALS patients who meet the HDE-approved device indications for use and undergo the surgical implantation procedure to receive the NeuRx DPS System after HDE approval. An important inclusion criterion is that patients must have chronic hypoventilation; an important exclusion criterion is that FVC < 45% predicted at time of surgery.
Sample Size Based on practical considerations in this small subpopulation of patients with ALS who meet the HDE indications for use, it is expected that 60 participants can be enrolled at 3 to 12 centers over three years. This sample size of 60 participants has 80% power to ensure that the major device-related adverse event rate at 9 months post implant does not exceed 40% (based on peak adverse event rate using same device for spinal cord injury indication [H070003]), assuming the true event rate is 23% (based on IDE), with 5% one-sided alpha. A sample size of 60 patients ensures that there will be at least 48 patients at risk at the beginning of the 6 to 9 months interval to analyze the AE rate at 9 months.
Data Collection This study will examine the following safety and probable benefit outcomes of interest:

Safety Outcome Measure: Occurrence of major device-related (including procedure-related) adverse events as defined as:

Serious capnothorax requiring invasive intervention (such as chest tube placement).

Mechanical ventilation for 24 hours or longer post-procedure.

Post-procedure extubation failure resulting in permanent tracheostomy ventilation (PTV).

Perioperative complication which delays the initiation of NeuRx DPS therapy.

Severe discomfort due to stimulation which is unable to be tolerated or resolved and results in interruption or discontinuation of NeuRx DPS therapy.

Device malfunction (e.g,. broken wire or stimulator) which interrupts or causes an undesired diminution of NeuRx DPS therapy (e.g., no stimulation in one hemi-diaphragm).

Electrode dislodgement from the diaphragm.

Wire infection.

Any other device- or procedure-related serious adverse event (SAE) that is fatal, life threatening, requires or prolongs hospitalization, or requires intervention to prevent permanent impairment or damage.

Probable Benefit Outcome Measure: Survival, defined as time to (a) death or (b) permanent tracheostomy mechanical ventilation (PTV) with discontinuation of pacing. (All deaths and PTV events will be reported regardless of relationship to the device or procedure.)

Follow-up Visits and Length of Follow-up 9 months

0 to 1 month, 1- 3 months, and every 3 months thereafter until post-implant follow-up completion

OSB Lead-NeuRx DPS Schedule

Report Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
six month report 03/28/2012 03/28/2012 On Time
one year report 09/27/2012 09/27/2012 On Time
two year report 09/27/2013 09/27/2013 On Time
three year report 09/27/2014 09/26/2014 On Time
four year report 09/27/2015 09/25/2015 On Time
five year report 09/26/2016 10/03/2016 Overdue/Received
Final Report 12/26/2016 02/15/2017 Overdue/Received

Contact Us

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD

Phone: (301) 796-6134
Fax: (301) 847-8140

Related Links